Physician profile
Joshua Mandrell
NPI 1770781650
$7,036.93
in general payments reported to CMS, 2019-2025
26 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $555 · 2021: $784 · 2022: $1,053 · 2023: $1,604 · 2024: $1,182 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,446 · Education: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,446.43 |
| Education | $512.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,751.74 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,629.11 | 2019-2025 | |
| Genzyme Corporation | $828.94 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $495.01 | 2019-2025 | |
| Lilly USA, LLC | $435.10 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $403.83 | 2019-2025 | |
| Incyte Corporation | $285.79 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $255.63 | 2019-2023 | Dupixent |
| Leo Pharma INC. | $241.77 | 2022-2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $105.63 | 2019-2022 | |
| Convatec INC. | $94.22 | 2024-2025 | |
| Amgen INC. | $89.27 | 2020-2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $87.22 | 2022-2023 | Sotyktu |
| Ucb, INC. | $77.76 | 2019-2021 | |
| Sandoz INC. | $36.29 | 2023-2024 | Hyrimoz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $33.30 | 2019 | |
| Janssen Scientific Affairs, LLC | $30.44 | 2019 | |
| Organogenesis INC. | $23.27 | 2023 | Puraply |
| Sensus Healthcare, INC. | $23.12 | 2019 | |
| Arcutis Biotherapeutics, INC. | $20.01 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.94 | 2022 | |
| Biofrontera INC. | $16.97 | 2025 | |
| Genentech USA, INC. | $13.86 | 2019 | |
| Biowound Solutions, INC. | $13.21 | 2025 | Bio-Connekt |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Dermira, INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Mandrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.